Literature DB >> 25469736

Lee Silverman Voice Treatment for people with Parkinson's: audit of outcomes in a routine clinic.

Sheila Wight1, Nick Miller.   

Abstract

BACKGROUND: Speaking louder/more intensely represents a longstanding technique employed to manage voice and intelligibility changes in people with Parkinson's. This technique has been formalized into a treatment approach and marketed as the Lee Silverman Voice Treatment (LSVT®) programme. Evidence for its efficacy has been published. Studies to date are dominated by research facility reports from the original LSVT® group or closely associated groups. Evidence for the efficacy of LSVT® in routine clinical settings is lacking. METHODS & PROCEDURES: We conducted an audit of outcomes for consecutive people with Parkinson's who were offered and completed LSVT® in a routine hospital outpatient setting. In- and exclusion criteria, assessment and treatment protocols followed precisely the methods stipulated by LSVT® Global. Additionally, participants completed the Voice Handicap Index (VHI) and 23 carers completed a visual analogue scale (VAS) for items relating to functional outcomes. OUTCOMES &
RESULTS: Group data (n = 33) revealed statistically significant increases in all objective and subjective measures at the end of treatment, though outcomes on the different measures revealed variable individual responses. Mean intensity increases on prolonged vowel were 9.3 dB post-treatment. Significant gains of mean 7.5 and 6.8 dB were maintained at 12 (n = 25) and 24 months (n = 15) respectively for those available for follow-up. Significant intensity gains occurred for reading post-therapy (mean = 8.5 dB), but changes reverted to statistically non-significant at 12 and 24 months. Intensity increase (mean = 8.5 dB) was significant for monologues post-therapy, but not at 12 and 24 months. Median VHI improvement was statistically significant post-therapy and at 12 months, but not at 24 months. Carer VAS ratings all improved significantly post-therapy; at 12 months only perceived loudness, strain, mumbling and intelligibility remained statistically significantly above baseline. No significant gains persisted to 24 months. CONCLUSIONS & IMPLICATIONS: LSVT® was successful for most individuals in this study. Not all patients attained significant changes by the end of treatment. Few patients who achieved significant gain at the end of treatment maintained this at 12 or 24 months. Implications for maintenance, interpretation of results in a degenerative condition and implications for further research are discussed.
© 2014 Royal College of Speech and Language Therapists.

Entities:  

Keywords:  Lee Silverman Voice Treatment; Parkinson's; speech and language therapy; voice

Mesh:

Year:  2014        PMID: 25469736     DOI: 10.1111/1460-6984.12132

Source DB:  PubMed          Journal:  Int J Lang Commun Disord        ISSN: 1368-2822            Impact factor:   3.020


  9 in total

1.  Aerodynamic findings and Voice Handicap Index in Parkinson's disease.

Authors:  Sergio Motta; Ugo Cesari; Mariano Paternoster; Giovanni Motta; Giuseppe Orefice
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-04-23       Impact factor: 2.503

2.  Feasibility of a Telerehabilitation Adaptation of the Be Clear Speech Treatment Program for Non-Progressive Dysarthria.

Authors:  Brooke-Mai Whelan; Deborah Theodoros; Louise Cahill; Atiyeh Vaezipour; Adam P Vogel; Emma Finch; Anna Farrell; Elizabeth Cardell
Journal:  Brain Sci       Date:  2022-01-31

3.  Design of the PERSPECTIVE study: PERsonalized SPEeCh Therapy for actIVE conversation in Parkinson's disease (randomized controlled trial).

Authors:  J J L Maas; N M De Vries; B R Bloem; J G Kalf
Journal:  Trials       Date:  2022-04-08       Impact factor: 2.279

4.  The Impact of PD Check-In, a Model for Supported Self-Managed Maintenance of Speech on the Quality of Life of People with Parkinson's Disease: A Phase 1 Study.

Authors:  Ann Finnimore; Deborah Theodoros; Anna Rumbach
Journal:  Brain Sci       Date:  2022-03-24

5.  Participants' perspective on a COVID-19 online vocal group stimulation for people with Parkinson's disease.

Authors:  Marie-Christine Hallé; Charline Delorme; Édith Coulombe; Ouswa Rekik; Ingrid Verduyckt
Journal:  Front Rehabil Sci       Date:  2022-08-02

6.  A retrospective study of long-term treatment outcomes for reduced vocal intensity in hypokinetic dysarthria.

Authors:  Christopher R Watts
Journal:  BMC Ear Nose Throat Disord       Date:  2016-02-01

7.  Telerehabilitation in Parkinson's disease: Influence of cognitive status.

Authors:  Alice Estevo Dias; João Carlos Papaterra Limongi; Wu Tu Hsing; Egberto Reis Barbosa
Journal:  Dement Neuropsychol       Date:  2016 Oct-Dec

8.  Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: a pilot randomised controlled trial (PD COMM pilot).

Authors:  Catherine M Sackley; Christina H Smith; Caroline E Rick; Marian C Brady; Natalie Ives; Smitaa Patel; Rebecca Woolley; Francis Dowling; Ramilla Patel; Helen Roberts; Sue Jowett; Keith Wheatley; Debbie Kelly; Gina Sands; Carl E Clarke
Journal:  Pilot Feasibility Stud       Date:  2018-01-10

9.  A serious game for speech training in dysarthric speakers with Parkinson's disease: Exploring therapeutic efficacy and patient satisfaction.

Authors:  Mario Ganzeboom; Marjoke Bakker; Lilian Beijer; Helmer Strik; Toni Rietveld
Journal:  Int J Lang Commun Disord       Date:  2022-03-26       Impact factor: 2.909

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.